Product
TAC
Aliases
Tacrolimus
4 clinical trials
6 indications
Indication
Liver TransplantIndication
kidney transplantIndication
Graft-Vs-Host DiseaseIndication
Transplant FailureIndication
Stem Cell Transplant ComplicationsClinical trial
A 60 Month, Single-arm, Proof-of-concept Study to Induce Allogeneic Tolerance in Deceased Donor Liver Transplant Recipients Using Siplizumab, an Anti-CD2 Antibody in Combination With Cyclophosphamide and SplenectomyStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients With TP53-Mutated, HER2 Negative Breast Cancer Receiving Neoadjuvant or Adjuvant Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)Status: Terminated, Estimated PCD: 2023-02-22
Clinical trial
Factors Affecting the Tacrolimus Blood Concentration and Its Impact on Transplant-related Outcomes in Pediatric HSCT Recipients: a Single-center Retrospective StudyStatus: Recruiting, Estimated PCD: 2024-09-29